amphotericin-b and Creutzfeldt-Jakob-Syndrome

Topics: Amphotericin B; Animals; Anticonvulsants; Antiparkinson Agents; Creutzfeldt-Jakob Syndrome; Disinfection; Humans; Mutation; Pentosan Sulfuric Polyester; PrPSc Proteins

There is currently no effective therapy available for Creutzfeldt-Jakob disease. However, a limited number of drugs such as polyanions, the amyloid-binding dye Congo red, amphotericin B and anthracyclines have been found to delay the appearance of the clinical signs in experimental prion diseases. Today, the most promising agent appears to be less toxic derivative the amphotericin B, MS-8209. Indeed this compound has a wide spectrum of anti-prion activity and constitute the unique molecule able to prolong survival time when treatment is performed at the late stages of infection. This result represents an important progress in therapeutical approaches of prion diseases and justify the development of new polyene antibiotic derivatives.

Topics: Amphotericin B; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antiviral Agents; Creutzfeldt-Jakob Syndrome; Disease Progression; Humans; Polyelectrolytes; Polymers; Prognosis

Clinical descriptions of Creutzfeldt-Jakob disease by the classical authors are compared with 209 transmitted cases at NIH between 1968-1992. Clinical comparison between Kuru, Gertsmann-Sträussler-Sheinker Syndrome and Creutzfeldt-Jakob disease. Fatal Familial Insomnia is included into the latter. Familial forms: new acquisitions.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antiviral Agents; Child; Creutzfeldt-Jakob Syndrome; Gerstmann-Straussler-Scheinker Disease; Humans; Iatrogenic Disease; Kuru; Middle Aged

Topics: Aged; Amphotericin B; Creutzfeldt-Jakob Syndrome; Female; Humans; Middle Aged; Treatment Outcome